Chlorhexidine Dihydrochloride

This article discusses clinical trials investigating the use of Chlorhexidine Dihydrochloride in combination with Diphenhydramine for patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) who have failed or become resistant to hypomethylating agent (HMA)-based treatments. These phase II studies aim to evaluate the efficacy and safety of this combination therapy in patients who have limited treatment options after HMA failure.

Table of Contents

What is Chlorhexidine Dihydrochloride?

Chlorhexidine Dihydrochloride is a chemical compound used in various medical applications. It’s important to note that this substance is also known by other names, including Chlorhexidine Hydrochloride, Chlorhexidine HCL, and Chlorhexidine Dichloride[1]. These different names all refer to the same active ingredient, which is commonly used for its antimicrobial properties.

Medical Uses

While the primary focus of the clinical trials mentioned in the source material is not on Chlorhexidine Dihydrochloride itself, we can provide some general information about its common uses:

  • Antiseptic: Chlorhexidine is widely used as an antiseptic, helping to prevent infections by killing or inhibiting the growth of microorganisms on the skin and mucous membranes[1].
  • Oral Care: It’s commonly used in mouthwashes and other dental products to help prevent plaque formation and gum disease.
  • Skin Preparation: Healthcare providers often use Chlorhexidine to clean the skin before surgical procedures or injections.
  • Wound Care: It can be used to clean and disinfect wounds, helping to prevent infections.

Administration

The method of administration for Chlorhexidine Dihydrochloride can vary depending on its specific use. In the context provided, it’s mentioned that the drug is administered intravenously[1]. However, it’s important to note that this is not the most common route of administration for Chlorhexidine. More typically, it’s used topically (applied to the skin) or as an oral rinse.

The dosage information provided in the source material indicates a maximum daily dose of 50 mg and a maximum total dose of 450 mg over a 9-week period[1]. However, these dosages may be specific to the particular study mentioned and not representative of all uses of Chlorhexidine Dihydrochloride.

Potential Side Effects

As with any medication, Chlorhexidine Dihydrochloride can potentially cause side effects. While the source material doesn’t provide specific information about side effects, some common ones associated with Chlorhexidine use can include:

  • Skin irritation or allergic reactions when used topically
  • Temporary staining of teeth when used as an oral rinse
  • Rarely, more serious allergic reactions

It’s important to discuss potential side effects with your healthcare provider before using any medication containing Chlorhexidine Dihydrochloride.

Precautions and Considerations

Based on the information provided in the clinical trial data, there are several important considerations when using medications containing Chlorhexidine Dihydrochloride:

  • Allergies: Patients with known allergies, hypersensitivity, or intolerance to Chlorhexidine or its components should not use this medication[1].
  • Pregnancy and Breastfeeding: Women who are pregnant, breastfeeding, or planning to become pregnant should consult with their healthcare provider before using this medication[1].
  • Other Medical Conditions: Patients with liver disease, including cirrhosis, should inform their healthcare provider before using this medication[1].
  • Drug Interactions: Always inform your healthcare provider about all medications you’re taking, including over-the-counter drugs and supplements, to avoid potential interactions.

Remember, the information provided here is general. Your healthcare provider is the best source of information about how Chlorhexidine Dihydrochloride might be used in your specific medical situation. Always follow your healthcare provider’s instructions and report any unusual symptoms or side effects promptly.

Aspect Details
Study Type Phase II clinical trials
Conditions AML and MDS failing or refractory to HMA-based treatment
Intervention Chlorhexidine Dihydrochloride and Diphenhydramine combination
Administration Intravenous
Primary Endpoint Overall response rate after 4 months of treatment
Key Inclusion Criteria AML or MDS diagnosis, HMA treatment failure, ≥5% bone marrow blasts
Key Exclusion Criteria Recent chemotherapy, prior intensive chemotherapy or stem cell transplant
Safety Monitoring Toxicity measured by NCI CTCAE v5.0
Quality of Life Assessment EORTC QLQ-C30 questionnaire

Ongoing Clinical Trials on Chlorhexidine Dihydrochloride

  • Study on the Effectiveness and Safety of Imetelstat for Patients with High-Risk Myelodysplastic Syndromes or Acute Myeloid Leukemia After HMA Therapy Failure

    Not yet recruiting

    2 1 1 1
    France Germany
  • Study on the Effectiveness of Imetelstat for Patients with High-Risk Myelodysplastic Syndromes or Acute Myeloid Leukemia After HMA Treatment Failure

    Not recruiting

    2 1 1 1
    France Germany

Glossary

  • Acute Myeloid Leukemia (AML): A type of cancer that affects the blood and bone marrow, characterized by the rapid growth of abnormal white blood cells that interfere with the production of normal blood cells.
  • Myelodysplastic Syndromes (MDS): A group of disorders caused by poorly formed or dysfunctional blood cells, which can lead to various health problems and may progress to acute myeloid leukemia.
  • Hypomethylating Agent (HMA): A type of drug used in cancer treatment that works by affecting DNA methylation, potentially reactivating tumor suppressor genes.
  • Cytopenia: A condition in which there is a lower-than-normal number of blood cells, which can affect red blood cells, white blood cells, or platelets.
  • Allogeneic Stem Cell Transplantation: A procedure in which a person receives blood-forming stem cells from a genetically similar, but not identical, donor.
  • ECOG Performance Status: A scale used to assess how a patient's disease is progressing and how it affects daily living abilities.
  • Progression-Free Survival: The length of time during and after treatment that a patient lives with the disease but it does not get worse.
  • Overall Response Rate: The proportion of patients whose cancer shrinks or disappears after treatment.
  • Quality of Life (QoL): A measure of an individual's well-being and ability to perform daily activities, often used to assess the impact of disease and treatment.
  • Bone Marrow Blasts: Immature blood cells in the bone marrow; a high percentage of blasts can indicate leukemia or other blood disorders.

References

  1. http://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-imetelstat-for-patients-with-high-risk-myelodysplastic-syndromes-or-acute-myeloid-leukemia-after-hma-therapy-failure/